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Approximately 1 in 500 middle aged people in the United States will be diagnosed with Polycystic Kidney 
Disease (PKD), an inherited genetic disorder that results in extreme cysts on the kidneys. PKD eventually 
leads to end-stage kidney failure and current treatments are limited to dialysis or transplantation. Thus, a 
pharmacological approach to prevent, delay, or slow the progression of PKD would revolutionize treatment 
and improve mortality. Interestingly, many proteins associated with PKD have been found in and around 
the primary cilia of renal epithelial cells. Cilia are small microtubule-based cellular appendages found on 
the surface of most cell types in the human body and are broadly classified as either “motile” or “primary” 
(immotile). Primary cilia are known to be mechano- and environmental sensors, and play a critical role in 
cell-to-cell communication. The aim of this proposed research is to use potential therapeutics identified in 
silico and in vitro in animal models of PKD to determine if the compound can delay or prevent cystogenesis. 
Here we test Sildenafil citrate (Viagra) in an animal model of rapidly progressing cyst formation for its 
ability to ameliorate the phenotype. Further research directed at understanding the cilia, cell-cycle, and 
cilia-mediated signalling activity will hopefully provide important insights into the mechanisms of renal 
cyst pathogenesis and lead to better approaches for therapeutic intervention for PKD. 
